Published in Blood Weekly, August 31st, 2006
The new name, effectively immediately, was chosen to better reflect the expanded scope of the company's new products and future strategic vision.
"The new name more accurately reflects our corporate objectives," stated President and CEO John W. Morgan. "While we began as a company focused on hemorrhage control, we are now expanding our platform technology into other markets and treatment areas where our solution constitutes a significant improvement in the current standard of care."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.